BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Manual for Notorious Fragrances: Immortal Aromas - 2Well informed: How to Take full advantage of Your Gadgets
- 37 Strange Apparatuses to Make Your Party Stick Out!
- 4'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity
- 5'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
- The 15 Most Powerful Forerunners in Business
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- Asia's Noteworthy Destinations: A Voyager's Aide
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- Dancing through the crackdown: The satirical song soundtracking post-Khamenei Iran
- Manual for Picking Coastline Travel
- Italian authorities detain civilian rescue ship, German NGO says
- IDF destroys Hamas shaft in northern Gaza with loaded 'ready to fire' rocket aimed at Sderot
- The moon up close: How the Artemis 2 astronauts are photographing their historic lunar flyby
